Home ›
Osteosarcoma Sarcoma Trials ›
NCT05182164
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
Phase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sarcomas.
Trial Details
NCT ID NCT05182164
Phase PHASE2
Sponsor Institut Bergonié
Status RECRUITING
Cancer Type Osteosarcoma Sarcoma
Interventions Association of pembrolizumab + cabozantinib
Locations (sample) Bordeaux, France|44.84124,-0.58046 Dijon, France|47.31344,5.01391 Lille, France|50.63391,3.05512 Lyon, France|45.74906,4.84789 Marseille, France|43.29695,5.38107
Key Eligibility Criteria
Histology: undifferentiated pleomorphic sarcoma (stratum 1), bone osteosarcoma (stratum 2), bone or extraskeletal or Ewing sarcoma (stratum 3), Advanced non resectable / metastatic disease, Recurrent disease or progression after standard therapy, Documented progression according to RECIST criteria.
For full eligibility, visit ClinicalTrials.gov .